ARNA Key Stats
- The 7 Least Obese U.S. States May 25
- The Top 3 Causes of Diabetes Fool May 25
- The 7 Least Obese U.S. States Fool May 24
- Why This Obesity Drug Is the Sector's Best Bet Fool May 24
- Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences PR Newswire May 24
- Novo obesity drug could launch in U.S. end 2014 May 24
- Arena - Good Sales, Bad Sales, Long And Short May 24
- First Manhattan Still Playing Hardball With Vivus May 24
- Arena Is Still A Great Short May 23
- Arena Buyout More 'Highly Probable' Than MannKind May 23
ARNA Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Arena Pharmaceuticals is up 37.43% over the last year vs S&P 500 Total Return up 27.77%, Vivus down 40.17%, and Orexigen Therapeutics up 88.05%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for ARNA
Pro Report PDF for ARNA
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download ARNA Pro Report PDF
Pro Strategies Featuring ARNA
Did Arena Pharmaceuticals make it into our Pro Portfolio Strategies?